GeneScience Pharmaceuticals Co., Ltd. announced that its long-acting anticancer drug, leuprolide mesylate injection (6M), has been approved for marketing by China’s National Medical Products Administration (NMPA) for the treatment of prostate cancer indicated for androgen deprivation therapy (ADT). The product is the first approved 6‑month long-acting subcutaneous injection formulation of leuprolide in China, extending the dosing interval of GnRHa therapy from the existing 1 or 3 months to 6 months — filling a gap in the field and providing a new, lower-frequency option for patients requiring long-term treatment.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Marketing approval |
| Product | Leuprolide mesylate injection (6M) – 6-month long-acting subcutaneous injection |
| Former Names | “Leuprolide injection emulsion,” “leuprolide mesylate suspension injection,” “LMIS 50mg” |
| Indication | Prostate cancer indicated for androgen deprivation therapy (ADT) |
| Registration Classification | Chemical Drug Category 5.1 |
| Approval Date | 10 Oct 2026 (announced) |
| Distinction | First approved 6-month long-acting leuprolide formulation in China |
Drug Profile & Mechanism of Action
- Molecule: Leuprolide mesylate, formulated as a long-acting gonadotropin-releasing hormone agonist (GnRHa) depot.
- Mechanism: Through continuous release of leuprolide in the body, the drug chronically occupies GnRH receptors, desensitizing the corresponding receptors on pituitary target cells.
- Downstream Effect: Receptor desensitization inhibits the pituitary-gonadal axis secretion of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and gonadal hormones, achieving the purpose of androgen deprivation therapy for prostate cancer patients.
- Formulation Technology: A depot-type in situ gel technology — the product forms a solid implant after injection that slowly degrades and releases the drug over time.
- Dosing Interval: The sustained-release design achieves a 6-month dosing interval, greatly improving patient medication compliance relative to 1- or 3-month regimens.
Disease & Treatment Context – Prostate Cancer ADT
- Cornerstone Therapy: Androgen deprivation therapy (ADT) remains the foundational systemic treatment for advanced prostate cancer, with GnRH agonists such as leuprolide among the most widely used agents worldwide.
- Chronic Treatment Burden: Prostate cancer is typically managed over years; with existing 1- and 3-month formulations, patients face repeated clinic visits and injections, a recognized driver of non-adherence and delayed dosing.
- The 6-Month Gap: Until this approval, no 6-month long-acting leuprolide formulation had been approved in China — the new product fills this gap, aligning China’s offering with the longest dosing intervals available internationally.
- Compliance Rationale: Fewer administrations per year reduce treatment burden for patients requiring long-term ADT, supporting more consistent hormone suppression.
Market Impact & Outlook
- Portfolio Positioning: The approval strengthens GeneScience Pharmaceuticals’ long-acting injectable franchise in oncology-adjacent endocrine therapy, adding a first-in-China differentiated formulation of an established molecule.
- Category 5.1 Pathway: Registered as Chemical Drug Category 5.1 (an imported-formulation-equivalent domestic long-acting product pathway), reflecting a formulation-innovation route rather than a new molecular entity.
- Competitive Landscape: The 6-month interval positions the product against existing 1- and 3-month leuprolide depots and other GnRHa formulations in China’s ADT market; pricing, reimbursement status, and launch timing were not disclosed.
- Patient Access: For the large population of Chinese prostate cancer patients on long-term ADT, half-yearly dosing offers a meaningful quality-of-life improvement in chronic disease management.
- Next Steps: Commercial rollout and any reimbursement listing process were not detailed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding leuprolide mesylate injection (6M), including its commercialization in China, patient adherence benefits, and market uptake in androgen deprivation therapy. Actual results may differ due to risks including pricing and reimbursement dynamics, competitive formulations, real-world safety and adherence experience, and market adoption. Launch details and financial terms have not been disclosed.-Fineline Info & Tech
